Study guide

11.2 Collaborative Pharmacy Practice Agreements

Kentucky MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Legal Hierarchy

1.1 Kentucky MPJE Format, Blueprint & CAT Mechanics 1.2 Federal vs. State Law Hierarchy & Stricter Law Rule 1.3 Kentucky Legal & Regulatory Infrastructure

2 Chapter 2: Kentucky Board of Pharmacy & Licensing Administration

2.1 Kentucky Board of Pharmacy Composition & Powers 2.2 Pharmacist Licensure, Examination & Reciprocity 2.3 License Renewal, Continuing Education & Discipline 2.4 Impaired Pharmacists, KYPRN & Reporting Duties

3 Chapter 3: Pharmacy Personnel: Interns, Technicians & PIC

3.1 Pharmacist Intern Registration & Scope of Practice 3.2 Pharmacy Technician Registration, Scope & Supervision 3.3 Pharmacist-in-Charge (PIC) Responsibilities & Governance

4 Chapter 4: Federal Drug Regulation & Supply Chain Standards

4.1 FDCA Drug Approval & Adulteration vs. Misbranding 4.2 Durham-Humphrey, Kefauver-Harris & Product Information 4.3 DSCSA Track-and-Trace & PPPA Safety Packaging

5 Chapter 5: Federal Controlled Substances Act Foundations

5.1 Controlled Substance Schedules & KY Specific Classifications 5.2 DEA Registration, Verification & Physical Security 5.3 Controlled Substance Ordering: Form 222 & CSOS

6 Chapter 6: Controlled Substance Dispensing, Theft & Disposal

6.1 Schedule II Prescriptions, 60-Day Validity & 3-Day Limit 6.2 Schedule III-V Dispensing, Refill Limits & Non-Rx Controls 6.3 Controlled Substance Theft, Loss & Disposal

7 Chapter 7: Prescriptive Authority & Kentucky Security Prescriptions

7.1 Prescriptive Scope: Independent & Mid-Level Practitioners 7.2 Kentucky Security Prescription Blanks & EPCS Mandate 7.3 Corresponding Responsibility & Red Flags

8 Chapter 8: Prescription Processing, Generic Substitution & Transfers

8.1 Prescription Requirements & Kentucky Labeling Standards 8.2 Kentucky Generic Drug Substitution & Biosimilars 8.3 Prescription Transfer Regulations 8.4 Refill Authority, Emergency Refills & Exceptions to Dispensing 8.5 Nonprescription, Behind-the-Counter & Restricted OTC Products

9 Chapter 9: Patient Care, Counseling & Health Privacy

9.1 Prospective Drug Utilization Review & Patient Profiles 9.2 Patient Counseling Standards in Kentucky 9.3 HIPAA Privacy, Security & Protected Health Information

10 Chapter 10: Kentucky KASPER PDMP & Opioid Public Health Laws

10.1 Kentucky KASPER Reporting Requirements 10.2 KASPER Query Mandates & Clinical Utilization 10.3 Naloxone Access, Standing Orders & Harm Reduction

11 Chapter 11: Board-Authorized Protocols & Advanced Clinical Practice

11.1 Kentucky Board-Authorized Protocols 11.2 Collaborative Pharmacy Practice Agreements 11.3 Kentucky Pharmacist Immunization Authority

12 Chapter 12: Pharmacy Operations, Compounding & Special Settings

12.1 Pharmacy Permits, Facility Standards & Record Retention 12.2 USP Non-Sterile (795), Sterile (797) & Hazardous (800) Compounding 12.3 Institutional, Automated Dispensing & Central-Fill Operations

13 Chapter 13: Drug Handling, Delivery & Facility Oversight

13.1 Return, Reuse & Redistribution of Dispensed Drugs 13.2 Drug Delivery, Mail Service & Remote Prescription Processing 13.3 Board Inspections, Permit Renewal, Reinstatement & Inactive Status 13.4 Discipline of Pharmacies & Permit Holders

11.2 Collaborative Pharmacy Practice Agreements

Key Takeaways Explain This Topic AI

Under 201 KAR 2:220 and KRS 315.010, Collaborative Pharmacy Practice Agreements (CPPAs) authorize pharmacists to provide Collaborative Drug Therapy Management (CDTM), including initiating, modifying, and discontinuing drug regimens and ordering laboratory tests.

Every CPPA must contain six essential statutory components: practitioner/pharmacist identification, authorized disease states/scope, detailed clinical protocols/algorithms, laboratory monitoring parameters, documentation/communication schedules, and annual review/renewal.

Patients must be fully informed that their drug therapy is managed under a collaborative practice agreement and must provide informed consent, retaining the absolute legal right to opt out at any time.

Pharmacists practicing under a CPPA are legally prohibited from diagnosing primary medical conditions (outside Board protocols) and cannot initiate Schedule II controlled substances without specific practitioner involvement.

All CPPA contracts, protocol algorithms, patient clinical intervention records, and laboratory tracking logs must be retained for a minimum of five (5) years.

Last updated: August 2026

11.2 Collaborative Pharmacy Practice Agreements

While Board-authorized protocols (201 KAR 2:380) provide population-level clinical algorithms for acute and preventive conditions, Collaborative Pharmacy Practice Agreements (CPPAs) governed by 201 KAR 2:220 and KRS 315.010 enable advanced, individualized Collaborative Drug Therapy Management (CDTM) . Under a CPPA, one or more licensed pharmacists collaborate directly with one or more physicians or authorized prescribers to manage complex chronic disease states, titrate specialty medications, order and evaluate laboratory tests, and optimize patient outcomes.

1. Statutory Authority & Definition of CDTM: 201 KAR 2:220 & KRS 315.010

In Kentucky, collaborative pharmacy practice is defined as a formal practice arrangement where an authorized practitioner delegates specified patient care responsibilities to a pharmacist pursuant to a written agreement: ┌─────────────────────────────────────────────────────────────────────────────┐

  • │ COLLABORATIVE PRACTICE CORE DEFINITIONS │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ STATUTORY DEFINITION: KRS 315.010(4) & 201 KAR 2:220 │
  • │ • 'Collaborative Pharmacy Practice Agreement' means a written agreement │
  • │ between one or more licensed pharmacists and one or more practitioners │
  • │ outlining the parameters for collaborative drug therapy management. │
  • │ │
  • │ 'COLLABORATIVE DRUG THERAPY MANAGEMENT' (CDTM) ENCOMPASSES: │
  • │ 1. Initiating, modifying, adjusting dosage, or discontinuing drug therapy; │
  • │ 2. Ordering, collecting, and evaluating laboratory and diagnostic tests; │
  • │ 3. Conducting targeted physical assessments and monitoring vital signs; │
  • │ 4. Providing comprehensive disease-specific patient education and monitoring│
  • │ │
  • │ PARTICIPATING PRACTITIONERS: │
  • │ • Allopathic Physician (MD) or Osteopathic Physician (DO) licensed in KY; │
  • │ • Advanced Practice Registered Nurse (APRN) practicing within statutory │
  • │ prescriptive scope; │
  • │ • Other authorized prescribers recognized under Kentucky medical statutes. │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Inpatient vs. Outpatient / Ambulatory Settings

Kentucky regulation 201 KAR 2:220 applies across diverse healthcare delivery environments:

Institutional / Health-System Settings: Hospital Pharmacy and Therapeutics (P&T) committee-approved medical staff protocols (e.g., pharmacokinetic vancomycin/aminoglycoside dosing, heparin/anticoagulation management, total parenteral nutrition [TPN] initiation, antimicrobial stewardship renal dosage adjustments).

Ambulatory & Community Outpatient Settings: Outpatient clinic-based or community pharmacy-based agreements managing chronic ambulatory conditions (e.g., Type 2 Diabetes insulin/GLP-1 titration, resistant hypertension medication adjustments, dyslipidemia lipid-lowering optimization, asthma/COPD step-therapy, anticoagulation INR management with warfarin or DOAC monitoring).

Loading diagram... Collaborative Pharmacy Practice Agreement (CPPA) Patient Care Workflow

2. The Six Essential Mandatory Components of a CPPA

Under 201 KAR 2:220, Section 2 , every Collaborative Pharmacy Practice Agreement must be in writing and contain the following six essential statutory elements : ┌─────────────────────────────────────────────────────────────────────────────┐

  • │ THE 6 MANDATORY CPPA COMPONENTS │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 1. Identification of Parties: │
  • │ • Full legal names, professional practice titles, Kentucky license │
  • │ numbers, practice sites, and signatures of all participating │
  • │ pharmacists and collaborating practitioners. │
  • │ │
  • │ 2. Scope of Practice & Authorized Disease States: │
  • │ • Explicit specification of the medical conditions and disease states │
  • │ authorized for collaborative management (e.g., diabetes, dyslipidemia, │
  • │ hypertension, anticoagulation, COPD, heart failure). │
  • │ │
  • │ 3. Clinical Protocols, Algorithms & Drug Formularies: │
  • │ • Detailed clinical guidelines and decision trees establishing precise │
  • │ criteria for initiating, modifying, titrating, substituting, or │
  • │ discontinuing authorized drug therapies. │
  • │ │
  • │ 4. Laboratory & Diagnostic Monitoring Parameters: │
  • │ • Specific laboratory tests and diagnostic procedures the pharmacist is │
  • │ authorized to order, perform, and evaluate, including testing frequency│
  • │ and clinical safety threshold limits (action levels). │
  • │ │
  • │ 5. Communication & Documentation Schedule: │
  • │ • Detailed timeline and mechanism for documenting patient encounters in │
  • │ the patient record and notifying the collaborating practitioner of all │
  • │ clinical interventions (typically within 24 to 48 hours). │
  • │ │
  • │ 6. Annual Review, Termination & Renewal: │
  • │ • Mandatory annual review date, explicit termination clauses, and │
  • │ re-execution procedures (must be re-evaluated at least every 12 months)│
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Details of Clinical Protocols & Dosage Adjustment Bounds

The clinical protocol attached to the CPPA cannot be vague or open-ended. It must delineate:

Specific drug categories, generic names, and dosage ranges authorized;

Objective biometric targets (e.g., target blood pressure < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg , target HbA1c < 7.0 % \text{HbA1c} < 7.0\% HbA1c < 7.0% , target INR 2.0 – 3.0 \text{INR } 2.0–3.0 INR 2.0–3.0 );

Action plans for adverse drug events, allergic reactions, or out-of-range laboratory values (e.g., serum potassium > 5.5 mEq/L > 5.5\text{ mEq/L} > 5.5 mEq/L , serum creatinine increase > 30 % > 30\% > 30% );

Mandatory referral thresholds where the pharmacist must suspend protocol modifications and immediately transfer management back to the physician.

3. Patient Informed Consent & Right to Opt Out

Patient autonomy is a fundamental legal cornerstone of collaborative practice in Kentucky:

Mandatory Patient Disclosure: Prior to the initiation of collaborative drug therapy management, the patient (or the patient's authorized legal representative) must be informed in writing or verbally that a licensed pharmacist is managing their drug therapy in collaboration with their physician pursuant to a CPPA.

Informed Consent: The patient must provide consent to participate in the collaborative arrangement. In outpatient ambulatory settings, this is typically documented via a signed collaborative care consent form in the medical record.

Absolute Right of Refusal / Opt-Out: A patient retains the absolute legal right to decline collaborative pharmacy care or revoke consent at any time without penalty or loss of standard medical care from the collaborating physician. If a patient opts out, the pharmacist must immediately document the refusal and transfer all medication management exclusively to the physician.

4. Prohibited Practices & Statutory Boundaries

To ensure clear division of clinical responsibility and protect patient safety, Kentucky law establishes strict statutory boundaries regarding what a pharmacist CANNOT do under a CPPA: ┌─────────────────────────────────────────────────────────────────────────────┐

  • │ PROHIBITED PRACTICES UNDER A CPPA │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 1. NO INDEPENDENT PRIMARY MEDICAL DIAGNOSIS: │
  • │ • A pharmacist practicing under a CPPA CANNOT independently establish a │
  • │ new primary medical diagnosis (e.g., diagnosing newly presenting │
  • │ rheumatoid arthritis or heart failure). The physician must diagnose │
  • │ the condition and refer the patient for collaborative management. │
  • │ • (Exception: CLIA-waived diagnostic screening under Board-Authorized │
  • │ Protocols pursuant to 201 KAR 2:380). │
  • │ │
  • │ 2. SCHEDULE II CONTROLLED SUBSTANCES PROHIBITED: │
  • │ • A CPPA CANNOT authorize a pharmacist to independently initiate, │
  • │ prescribe, or dispense Schedule II controlled substances (e.g., C-II │
  • │ opioid analgesics, C-II amphetamine ADHD psychostimulants). │
  • │ • Any initiation of Schedule II controlled drugs requires direct, │
  • │ independent practitioner order and prescription. │
  • │ │
  • │ 3. PRACTICING OUTSIDE CPPA SCOPE: │
  • │ • Managing a disease state not explicitly enumerated in the signed CPPA │
  • │ constitutes practicing medicine without a license and grounds for │
  • │ disciplinary revocation under KRS 315.121. │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • 5. High-Yield Comparison: Board Protocols vs. Collaborative Practice Agreements

A classic testing focus on the Kentucky MPJE is comparing Board-Authorized Protocols ( 201 KAR 2:380 ) with Collaborative Pharmacy Practice Agreements ( 201 KAR 2:220 ):

Regulatory Dimension Board-Authorized Protocol (201 KAR 2:380) Collaborative Practice Agreement (201 KAR 2:220)

Clinical Focus Acute, self-limiting conditions & public health preventive services (Flu, Strep, UTI, Tobacco, PrEP, Vaccines) Complex, chronic disease states & inpatient therapeutic drug monitoring (Diabetes, HTN, Anticoagulation, TPN, Vancomycin)

Patient Relationship Population-level protocol; no prior physician diagnosis required for the individual encounter Individual patient referral following primary medical diagnosis by collaborating physician

Prescribing / Dispensing Scope Pharmacist initiates dispensing of specific non-controlled medications from a Board-approved formulary Pharmacist initiates, adjusts, titrates, substitutes, and discontinues medications within CPPA algorithms

Diagnostic Authority Pharmacist performs CLIA-waived point-of-care diagnostic tests (strep swab, flu test, urinalysis, HIV test) Pharmacist orders, collects, and evaluates comprehensive laboratory tests (CBC, CMP, lipid panels, INRs, therapeutic drug levels)

Board Registry Requirement MANDATORY submission to the Kentucky Board of Pharmacy protocol registry prior to implementation Maintained at practice site; available for Board inspection upon request (hospital P&T approval satisfies inpatient)

Controlled Substances STRICTLY PROHIBITED (No C-II to C-V) No Schedule II initiation ; limited C-III to C-V management only if explicitly authorized in agreement and compliant with DEA

Review Frequency Re-executed according to protocol schedule / Board updates Mandatory Annual Review & Re-Execution (every 12 months)

Record Retention Five (5) Years from the date of service Five (5) Years from the date of service / termination